Stryker completes acquisition of Artelon

USA—Stryker, a US-based medical device company, has announced the completion of its acquisition of Artelon, a company specializing in soft tissue fixation, aimed at expanding its reach in a surgical market estimated to be worth approximately US$3.4 billion.

The acquisition is intended to integrate Artelon’s portfolio of devices into Stryker’s offerings, enhancing the options available to its foot and ankle, sports medicine, and specialist customers.

In a statement, Stryker highlighted that Artelon’s synthetic technology is designed to enhance biological and mechanical ligament and tendon reconstruction, with more than 60,000 implantations worldwide.

Although the financial details of the acquisition have not been disclosed, the announcement had an immediate impact on the market, with Stryker’s stock price falling from US$339 per share to US$333 per share.
Meanwhile, Skyler’s competitor Conmed spent US$85 million to complete its Biorez acquisition, with an additional US$165 million in potential future payments, according to Medtechdive.

Zimmer, on the other hand, has agreed to a $155 million deal, with an extra US$120 million in regulatory and commercial markers spread over three years.

Commenting on this acquisition, Tim Lanier, President of Stryker’s Trauma & Extremities division, emphasized that integrating Artelon’s portfolio into Stryker’s offerings would allow them to deliver best-in-class soft tissue fixation solutions.

Lanier added that this acquisition strengthens their competitive edge by leveraging Artelon’s unique synthetic technology and extensive expertise. It positions them to drive innovation and solidify their leadership in the foot and ankle and sports medicine segments.

Brent Ladd, President of Stryker’s Endoscopy division, echoed these sentiments, stating that acquiring Artelon will offer enhanced solutions in the soft tissue fixation segment, thereby improving their ability to meet the diverse needs of their customers.

Ladd noted that this acquisition marks a significant milestone for Stryker, as it will provide customers with advanced technologies designed to improve patient outcomes.

This announcement follows a series of strategic acquisitions by Stryker across multiple indications.

In May 2023, Stryker acquired Cerus Endovascular, a commercial-stage medical device company.

Furthermore, in 2018, Stryker acquired spine solutions maker K2M Group in an all-cash deal valued at US$1.4 billion.

Sign up to receive our email newsletters  with  latest news updates and  insights from Africa and the World HERE